Contact
searchSearch
HMP Global
Login
Quiz

Quiz: Prognostic Efficacy of Electronic Total Tumor Infiltrating Lymphocytes

11/30/2022

Related Content

News
Five-Year KEYNOTE-942 Results Show Durable Benefit With Intismeran Plus Pembrolizumab in Resected Melanoma
08/27/2026
Stephanie Holland
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase...
08/27/2026
Oncology
News
Intismeran Plus Pembrolizumab Outperforms Pembrolizumab Alone in Resected Stage IIB-IV Melanoma
08/19/2026
Stephanie Holland
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3...
08/19/2026
Oncology
News
Spartalizumab Triplet Extends Overall Survival in BRAF V600–Mutant Advanced Melanoma
08/18/2026
Stephanie Holland
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3...
08/18/2026
Oncology
Diwakar Davar, MBBS
Videos
PRAME-Directed T-Cell Receptor Therapy Demonstrates Durable Responses in Advanced Melanoma
08/18/2026
Diwakar Davar, MBBS
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses...
08/18/2026
Oncology

Recent News

FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology
News
Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
09/15/2026
Emily Estrada
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3...
09/15/2026
Oncology
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use